Cancer Treatment Today

The oral PARP inhibitor olaparib is approved for the treatment of patients with recurrent ovarian cancer and a BRCA mutation, and it has been shown to provide clinically meaningful benefit among such patients. There is a case report of oaparib in colon leiomyosarcoma, which is not sufficient to support medical necessity. Sargos et al reported a page IB study of olaparib with concomitant radiotherapy in locally advanced/unresectable soft-tissue sarcoma from the French Sarcoma Group.There is an ongoing phase II study of trabectidin and olaparib in Treating Patients with Advanced Unresectable or Metastatic Sarcoma; it is nto a randomized study.
A recent study in leiomyosarcoma conlided that Olaparib and temozolomide met the prespecified primary end point and provided meaningful clinical benefit in patients with advanced, pretreated uLMS. A found several ssmal studies or case-reprots in various sarcoma types of oaparib with or without other agents.
Paul Sargos, Marie Pierre Sunyach, Anne Ducassou et al, Preliminary results of a phase IB study of olaparib with concomitant radiotherapy in locally advanced/unresectable soft-tissue sarcoma from the French Sarcoma Group. Journal of Clinical Oncology > List of Issues > Volume 40, Issue 16_suppl 2022.
Matthew Ingham et al., Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250). JCO 41, 4154-4163(2023).

Grignani, Giovanni et al, Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group. The Lancet Oncology, Volume 19, Issue 10, 1360 – 1371

Hamdan D, Marisa L, Tlemsani C, Angeli E, Soussan M, Derive N, Laurent-Puig P, Bousquet G. Olaparib in the
Setting of Radiotherapy-Associated Sarcoma: What Can Precision Medicine Offer For Rare Cancers? JCO Precis Oncol. 2023

Choy, E., Butrynski, J.E., Harmon, D.C. et al. Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy. BMC Cancer 14, 813 (2014). https://doi.org/10.1186/1471-2407-14-813

Ingham M, Allred JB, Chen L, et al. Phase II study of olaparib and temozolomide for advanced uterine leiomyosarcoma (NCI Protocol 10250). Published online July 19, 2023.J Clin Oncol. doi:10.1200/JCO.23.00402

Paul Sargos, Marie Pierre Sunyach, Anne Ducassou et al, Preliminary results of a phase IB study of olaparib with concomitant radiotherapy in locally advanced/unresectable soft-tissue sarcoma from the French Sarcoma Group. Journal of Clinical Oncology > List of Issues > Volume 40, Issue 16_suppl 2022.

Choy, E., Butrynski, J.E., Harmon, D.C. et al. Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy. BMC Cancer 14, 813 (2014).

In GK, Hu JS, Tseng WW. Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations. Ther Adv Med Oncol. 2017 Aug;9(8):533-550